Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P E Konicki

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Psychopharmacology Bulletin|January 1, 1989
Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behaviorP E Konicki, S C Schulz
Schizophrenia Research|December 22, 2007
Clozapine: toxicity vs. postmortem redistributionGeorge E Jaskiw, P E Konicki, Matthew A Fuller
Life Sciences|January 1, 1991
The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patientsP E Konicki, R R Owen, R E Litman, et al.
Journal of Medicinal Chemistry|November 1, 1983
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivoK C Rice, P E Konicki, R Quirion, et al.
Modern Problems of Pharmacopsychiatry|January 1, 1990
Neurochemical and neural mechanisms of positive and negative symptoms in schizophreniaD Pickar, R E Litman, P E Konicki, et al.
Journal of Clinical Psychopharmacology|August 1, 1996
Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsiaM A Fuller, G Jurjus, K Kwon, et al.
International Journal of Geriatric Psychiatry|May 1, 1997
Outcome of clozapine therapy for elderly patients with refractory primary psychosisM Sajatovic, G Jaskiw, P E Konicki, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 1, 1993
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patientsM H Rapaport, O Wolkowitz, J R Kelsoe, et al.
The Journal of Clinical Psychiatry|March 1, 1997
Clozapine and associated diabetes mellitusA P Popli, P E Konicki, G J Jurjus, et al.
Acta Psychiatrica Scandinavica|December 5, 2013
Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patientsM C Davis, M A Fuller, M E Strauss, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Psychopharmacology Bulletin|January 1, 1989
Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behaviorP E Konicki, S C Schulz
Schizophrenia Research|December 22, 2007
Clozapine: toxicity vs. postmortem redistributionGeorge E Jaskiw, P E Konicki, Matthew A Fuller
Life Sciences|January 1, 1991
The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patientsP E Konicki, R R Owen, R E Litman, et al.
Journal of Medicinal Chemistry|November 1, 1983
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivoK C Rice, P E Konicki, R Quirion, et al.
Modern Problems of Pharmacopsychiatry|January 1, 1990
Neurochemical and neural mechanisms of positive and negative symptoms in schizophreniaD Pickar, R E Litman, P E Konicki, et al.
Journal of Clinical Psychopharmacology|August 1, 1996
Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsiaM A Fuller, G Jurjus, K Kwon, et al.
International Journal of Geriatric Psychiatry|May 1, 1997
Outcome of clozapine therapy for elderly patients with refractory primary psychosisM Sajatovic, G Jaskiw, P E Konicki, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 1, 1993
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patientsM H Rapaport, O Wolkowitz, J R Kelsoe, et al.
The Journal of Clinical Psychiatry|March 1, 1997
Clozapine and associated diabetes mellitusA P Popli, P E Konicki, G J Jurjus, et al.
Acta Psychiatrica Scandinavica|December 5, 2013
Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patientsM C Davis, M A Fuller, M E Strauss, et al.
Pageof 2